
1. j infect dis. 2011 jan 15;203(2):207-10. doi: 10.1093/infdis/jiq024. epub 2010
dec 9.

methotrexate highly potent pyrimethamine-resistant plasmodium vivax.

imwong m(1), russell b, suwanarusk r, nzila a, leimanis ml, sriprawat k,
kaewpongsri s, phyo ap, snounou g, nosten f, renia l.

author information: 
(1)department molecular tropical medicine genetics, faculty tropical
medicine, mahidol university, bangkok.

comment in
    j infect dis. 2011 jan 15;203(2):144-5.

resistance vivax malaria treatment antifolates, pyrimethamine 
(pyr), spreading mutations dihydrofolatereductase (dhfr) genes are
selected disseminated. tested antitumor drug methotrexate (mtx), a
potent competitive inhibitor dhfr, 11 plasmodium vivax isolates ex
vivo, 10 multiple dhfr mutations associated pyr resistance.
despite high-grade resistance pyr (median 50% inhibitory concentration [ic₅₀],
13,345 nm), parasites highly susceptible mtx (median ic₅₀, 2.6 
nm). given potency pyr-resistant p. vivax, antimalarial potential
of mtx deserves investigation.

doi: 10.1093/infdis/jiq024 
pmcid: pmc3071051
pmid: 21288820  [indexed medline]

